A maximum dose of 800 mg/day is permitted.
Nonsteroidal antiinflammatory drugs and per-oral prednisolone to a maximum dose of 10 mg daily were permitted in both groups.
Any patient who cannot tolerate the maximum dose specified in the protocol due to toxicity or intolerance, is permitted to continue on the highest tolerable dose and then progress to the next step in the protocol if required.
Concomitant oral glucocorticoids (≤10 mg/day prednisone or equivalent) and non-steroidal anti-inflammatory drugs (up to the maximum recommended dose) were permitted if patients were on a stable dose for 4 weeks or longer before baseline.
At 3 years, 23% of the medical arm patients were on an increased dose of esomeprazole to control their symptoms, 8% on the maximum permitted dose schedule (fig 3).
On March 15th the plant reported a dose at the perimeter of 11.9mSv an hour (though this dropped back to 6mSv), meaning a worker's maximum permitted dose for a year would be exceeded in a single shift.
Entry to the study was permitted for patients with doses of OCS of ≤1.0 mg/kg/day (maximum dose 80 mg/day).
This depends on the maximum circuit flow permitted by the access catheter, which in turn determines the maximum dose, assuming that the countercurrent flow to blood flow ratio should be <0.3 with diffusive CRRT, or a filtration fraction with convective therapy <0.2 [ 2].
All patients in the ATX group who weighed less than 70 kg were started on a daily dose of approximately 0.5 mg/kg body weight, the final target daily dose being 1.2 mg/kg, with a maximum permitted daily dose of 1.4 mg/kg.
